J&J orthopedics unit draws Apollo interest in potential $20 billion deal, Bloomberg News reports

Johnson & Johnson is currently engaged in discussions regarding the sale of its orthopedics unit, specifically its hips-and-knees business, to Apollo Global. According to reporting from the Wall Street Journal and Bloomberg, the potential acquisition is valued at approximately $20 billion. This transaction would see the ownership of the specialized orthopedic division transition from the healthcare giant to the private equity firm. Multiple major news outlets have tracked the development, with Bloomberg News serving as a primary source for the reports. Reuters has highlighted the interest shown by Apollo in this potential $20 billion arrangement.

Simultaneously, the Wall Street Journal provided specific details regarding the nature of the business being sold, identifying it as the hips-and-knees segment. Seeking Alpha and Yahoo Finance have also reported on the ongoing talks between the two entities, ensuring that the potential divestiture is widely recognized across both general news and financial analysis channels. The market responded to the reports with a slight increase in J&J's stock price during after-hours trading, as noted by Yahoo Finance. This movement reflects investor reactions to the possibility of a multi-billion dollar cash infusion from the sale of the orthopedics division. The context of the deal involves a strategic shift for Johnson & Johnson, moving away from certain medical device sectors.

By selling the orthopedic unit to Apollo Global, J&J would be separating a significant portion of its surgical and joint replacement business from its broader corporate portfolio. Observers are now watching to see if the discussions between Johnson & Johnson and Apollo Global will culminate in a finalized agreement. The coverage does not yet specify a closing date or the exact terms of the contract beyond the reported $20 billion valuation. Future updates will likely center on whether the deal receives regulatory approval and how the transition of the hips-and-knees business will be managed. Market analysts and investors continue to monitor JNJ stock for further volatility as more details regarding the potential sale are disclosed by the involved parties.